Abbott (ABT) Q3 Earnings Put Margin Gains Against Nutrition Risk

Abbott Laboratories just reported Q3 2026 earnings with adjusted EPS at US$1.42 and comparable sales growth of 7%, yet the stock slipped about 1.9% to US$100.51 into today’s close. Traders are treating this like a routine quarter. The real story sits in profitability. Gross margin reached 57.2% and operating margin touched 23.4%, both higher than a year ago. This matters for a medical devices and diagnostics heavyweight, where every point of margin shapes long term value far more than a one day price reaction.

Like the margin profile Abbott Laboratories just reported but unsure whether you want more balance sheet strength baked into your watchlist? Compare ABT with a curated group of peers built around solid profitability and sturdy finances in our list of solid balance sheet and fundamentals stocks (25 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$13,013 million vs. US$11,369 million (up about 14.5%)
• Net Income, Excl. Extra Items (Q3 2026 vs. Q3 2025): US$920 million vs. US$1,644 million (down about 44.0%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.53 vs. US$0.94 (down about 43.9%)
• Margins (Q3 2026 vs. Q3 2025): Gross margin 57.2% vs. prior year level not specified; operating margin 23.4% vs. prior year level not specified (both described as higher year over year)

Ask Charlie what Abbott said post-spin margins look like.

Abbott’s Device Engine: Progress With Caveats

Abbott Laboratories has pitched devices and diagnostics as the future earnings engine. Q3 gives an early read on how that promise is translating into real business.

"The main thing that has to go right is that Abbott Laboratories continues to convert its medical technology pipeline in areas like continuous glucose monitoring, electrophysiology and cancer diagnostics into sustained sales growth and margin expansion, while managing Nutrition legal and regulatory risks."

Medical Devices grew 8% with electrophysiology and rhythm leading, Cancer Diagnostics advanced 14%, and Libre sales rose 8%. Gross and operating margins both improved, and management is targeting further margin lift once Nutrition is separated, so the execution path appears aligned with that ambition so far.

Nutrition Legal Overhang: Ring-Fenced, Not Gone

Legal drag around Nutrition was a core worry for Abbott Laboratories, and the quarter reframes that risk rather than removing it.

"The large infant formula settlements of about US$670 million for NEC litigation and US$385 million related to the 2022 Sturgis recall show that Abbott Laboratories still carries legal and regulatory exposure in Nutrition, and further actions or follow on claims could keep legal costs elevated and hold back net margins and earnings."

Q3 margins expanded despite those past settlements, and management now plans a tax free spin off of the US$8.5b Nutrition unit. That move ring fences most Nutrition exposure but does not fully erase reputational and policy scrutiny, including the ongoing focus on Abbott’s tax practices.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Hunt For Quiet Mispricings

Abbott Laboratories just showed how a cleaner margin story can draw a mixed price reaction. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 46% below our estimate - uses a record backlog of mega projects and Indo Pacific defense work to secure higher margin contracting.
• Company 2 - 38% below our estimate - grows fee income as newer capital markets and private capital mandates move larger transactions onto its advisory platform.
• Company 3 - 49% below our estimate - builds primary small business relationships by scaling digital loan origination and business checking while keeping credit performance and expenses controlled.

That is three of the list. See every one of the 33 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com